Avacincaptad pegol (IZERVAYTM, Astellas, Japan), a complement C5 inhibitor, and Pegcetacoplan (SYFOVRETM, Apellis, MA, USA), a targeted complement C3 inhibitor, represent recent advancements in the treatment of dry AMD. This evidence concerns the gene C3 and dry age related macular degeneration.